Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202300 | 1.00 | ACE (0.48) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL202301 | 1.00 | ACE (0.48) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL16187224 | 0.87 | ATM (0.45) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL14237836 | 0.87 | ATM (0.45) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL26077743 | 0.87 | ATM (0.45) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL1249539 | 0.87 | HSD17B10 (0.46) | ATMHSD17B10SMN1; SMN2USP2PREP | |
| SCHEMBL3509553 | 0.85 | ATM (0.44) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL9879848 | 0.85 | ATM (0.44) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL3509552 | 0.85 | ATM (0.44) | ACEATMHSD17B10SMN1; SMN2USP2 | |
| SCHEMBL1021093 | 0.85 | ATM (0.44) | ACEATMHSD17B10SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118634264-A | Efficient composite traditional Chinese medicine antibacterial agent and preparation method and application thereof | 博尔纳生物科技(江门)有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-116925193-A | Method for synthesizing polypeptide for preventing or treating novel coronavirus | 深圳翰宇药业股份有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-111057128-B | Sulfur-containing isoindolone cyclic peptide derivative and preparation method thereof | 哈尔滨师范大学 | 2023-05-16 | — | — | CN | claimed |
| US-20040030155-A1 | Process for preparing active esters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | claimed |
| EP-1350790-A1 | PROCESS FOR PREPARING ACTIVE ESTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-08 | — | — | EP | claimed |
| US-12624122-B2 | Affinity maturated TAG72 specific single chain antibodies | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12612598-B2 | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4720088-A1 | CONSTRAINED PEPTIDE INHIBITORS OF LRRK2-FADD INTERACTIONS | University of Georgia Research Foundation, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720089-A1 | COMPOSITIONS AND METHODS FOR IMAGING AND TREATING ENDOMETRIOSIS | Endomet Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4713348-A1 | DOUBLY CONSTRAINED PEPTIDES AS ALLOSTERIC INHIBITORS OF LEUCINE RICH REPEAT KINASE 2 | University of Georgia Research Foundation, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4662235-A1 | METHOD OF CHEMICAL SYNTHESIS OF SINGLE-CHAIN ANTIBODY FRAGMENTS AND PRODUCTS THEREBY OBTAINED | Figini, Mariangela (IT) | 2025-12-17 | — | — | EP | disclosed |
| EP-0574135-B1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORP (JP) | 1998-11-18 | — | — | EP | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5644028-A | Process for producing peptide derivatives and salts therefor | JAPAN ENERGY CORPORATION (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0574135-A1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORPORATION (JP) | 1993-12-15 | — | — | EP | disclosed |
| WO-1993001174-A1 | THIAZOLIDINE DERIVATIVES AND THEIR USE AS ANTI-VIRAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
| US-4904680-A | IMMUNOLOGY | SANKYO COMPANY, LIMITED (JP) | 1990-02-27 | — | — | US | disclosed |
| EP-0173441-B1 | AMINO ACID DERIVATIVES HAVING ANTI-TUMOR ACTIVITY AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1990-01-24 | — | — | EP | disclosed |
| EP-0173441-A1 | Amino acid derivatives having anti-tumor activity and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612598-B2 | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy | IL2, ICOS, IL2RA | ACE 4748/4885ATM 163/4885HSD17B10 2793/4885 |
| US-20040030155-A1 | Process for preparing active esters | CES1, CYP3A4, CYP3A5 | ACE 289/4885ATM 4804/4885HSD17B10 123/4885 |
| US-12624122-B2 | Affinity maturated TAG72 specific single chain antibodies | IGLV6-57, CD74, IGSF11 | ACE 4528/4885ATM 2769/4885HSD17B10 3717/4885 |
| US-12565520-B2 | Chemically-stabilized allosteric modulators of leucine-rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | ACE 4066/4885ATM 424/4885HSD17B10 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.